The rising rate of antimicrobial drug resistance in Enterobacteriaceae reduces the number of reliably effective drugs that can be used to treat infections.
Introduction
Worldwide, Intensive care units (ICUs) are faced with increasing rapid emergence and spread of antibiotic-resistant Gram-negative bacteria and Gram-positive bacteria. Gram negative bacteria producing β-lactamases that are resistant to many other antibiotics and very few antimicrobial agents remain effective as treatment option. Since the initial description of Extended Spectrum βlactamases (ESBLs) production by Klebseilla pneumonia & Escherichia coli in the 1980s [1] , strains of Enterobacteriaceae resistant to third-generation cephalosporins are increasingly being recognized [2] . ESBL-producing Enterobacteriaceae strains have been frequently implicated in outbreaks in Pediatrics Intensive Care Unit (PICUs) and Neonatal Intensive Care Unit (NICU) [3] . Therefore, there have been many recent calls to intensify current infection control efforts aimed at reducing the emergence and dissemination of infections caused by antibiotic-resistant bacteria [4] [5] [6] [7] . The widespread use of cefriaxone and/or cefotaximine has been proposed as a reason for the emergence of CTX-M enzymes. The increased frequency of isolation & reporting of CTX-M ESBLs is alarming and is likely to represent only the tip of iceberg for the underdeveloped continents where molecular technology for the analysis of ESBL enzymes is scares. The loss of oxyaminocephalosporins for the treatment of infections represents a serious problem that seems to reach unprecedented level globally [4] . Currently, the most widely distributed CTX-M enzyme is CTX-M-15 which is detected in E. coli and other Enterobacteriaceae members from India in 2001 [5] and now also been reported in several countries, including the United Kingdom [6] , Italy, Turkey, Japan, Norway, France, Canada [6] .
Two recent studies using multilocous sequencing typing (MLST) Identified a single clone of CTX-M-15 producing E. coli named ST 131 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . This clone is associated with community as well as hospital acquired infections. In our hospital, we found a marked increased in the numbers of ESBL-producing Enterobacteriaceae in the PICUs & NICUs.
According to World Health organization (WHO) estimates, there are about 5 million neonatal deaths a year, 98% occurring in developing countries. Infection, prematurity, and birth asphyxia are the main causes. The most common cause of death in the neonatal period are infections, including septicaemia, meningitis, respiratory infections, diarrhea and neonatal tetanus. Overuse of antimicrobial agents has been identified as an important factor in the emergence of antibiotic resistant bacterial infections in the ICUs. Several investigators have demonstrated a close association between previous use of antibiotics and the emergence of subsequent antibiotic resistance in both gram-negative and gram-positive bacteria. Nosocomial blood stream infections are among the most serious infections acquired by ICU patients. ESBLs are now problem in hospitalized patients worldwide. The ESBL phenomenon began in Europe, most likely because expanded-spectrum β-lactam antibiotics were first used there. The prevalence of ESBLs among clinical isolates varies from country to country and from institution to institution. According to CDC-National Nosocomial Infections surveillance), in the United States occurrence of ESBL production in Enterobacteriaceae ranges from 0 to 25%, depending on the institution, with the national average being around 3%. Major risk factors for colonization or infection with ESBL producing organisms include length of hospital stay, severity of illness, long stay in the ICU, incubation and mechanical ventilation, urinary or arterial catheterization, surgery, extended abuse of broad spectrum antibiotics [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . More recently systematic attempts have been made to look at clinical outcomes of bacteremia caused by ESBL-producing strains E. coli and Klebseilla pneumonia strains. Epidemiological data are limited regarding ESBL CTX-M-15 from India. To further delineate the mode of successful dissemination of ESBLs CTX-M-15 and to gain insights into the mechanism underlying this phenomenon we designed this study to assesses clonality & diversity of Enterobacteriaceae strains isolated from PICUs and NICUs of our hospital. Sample Processing-Blood sample were incubated in Bact T alert 3D and will be process on Blood Agar and MacConkey agar and incubated at 37°C. Identification and confirmation will be done by standard conventional methods.
Methodology

Place of Conducting
Isolation, identification and confirmation of gram negative bacteria were done by standard conventional methods [11] [12] [13] . Antibiotic susceptibility testing were done by Kirby Bauer ̓s disc diffusion technique and interpretations of susceptibility will be done according to the CLSI (Clinical Laboratory Standard Institute) 2008 guidelines. The following antibiotic disc manufactured by Hi-Media will be used for testing the isolates [1] [2] [3] [4] [5] .
Double Disk Approximation Test (DDAT) [for ESBL Phenotypic Detection]
PCR Detection of O25b-ST131 CTX-M-15 Clone Isolates
The newly described O25b O type E. coli were detected by using the following primers gndbis.f (5'ATACCGACGACGCCGATCTG-3') and rfbO25b.r (5'TGCTATTCATTATGCGCAGC-3').
Annealing temperature of 60ºC was used to generate a PCR product of 300bp with the conditions as described [7] . The reaction mixture (total volume 10ul) contained 1ul of 10X PCR buffer, 0.2 µl of 10 mM dNTP mixture, 0.2 ul of 10 p mol/ul primers, 100 ng of genomic DNA and 0.5 unit of Taq DNA polymerase. PCR amplification was performed in eppendorf thermo cycler with the following temperature profile: initial denaturation at 95°C for 5 mins, followed by 35 cycles each of denaturation at 94°C for 45 sec, annealing at 59°C for 45 sec and extension at 72°C for 45 sec, and a final extension at 72°C for 10 min. The amplified products obtained were checked by running on a 1.5% Agarose gel [1] [2] [3] [4] [5] [6] [7] [8] .
Observations and Results
Total of 100 blood samples were received from PICU and NICU during the study period of two months. Of this 80(80%) samples showed growth in culture and sensitivity testing and male predominance was seen i.e. male 50(62.5%) and female 30(37.5%) [Fig-1 ]. 
Fig. 1-
Discussion
The emergence and spread of infections caused by resistant microorganisms has been rising worldwide. Since 1980s ESBLs in Klebseilla pneumonia and E. coli had been documented and recent reports indicates that the widespread use of carbapenem, the agents reliably active against these bacteria, resulted in the emergence of a new resistance of metallo-β-lactamases. Recently, the increase of ESBLs and MBLs production in Enterobacteriaceae has become a major concern globally. In our hospital, we found alarming increasing in the number of the ESBL and MBL producing Enterobacteriaceae in PICU and NICU.
In the present study 80% samples showed growth and followed for identifications and sensitivity. We found male preponderance i.e. 50(62.5%) and female were 30(37.5%). Among 80 bacterial isolates, 55(68.75%) were Gram negative bacteria while 25(31.25%) were gram positive cocci [Table-1 ]. Of the total 55 Gram negative bacteria, Klebseilla pneumonia were 17(30.90%), E. coli 13 (23.63%) Acinetobacter spp. 10(18.18%), Citrobacter spp. 3 (5.45%) Enterobacter cloacae 1(1.81%) and Salmonella typhi 1 (1.81%). All isolates were screened for detection of production of ESBL and results were recorded. It showed that of the 55 GNB isolates-17 (63.63%) were resistant to ceftazidime and 10 (18.185%) were confirmed phenotypically as ESBL producers and only one isolate of Acinetobacter baumanii were MBL producer [Table-2 . It is now the most widely distributed CTX-M worldwide. The present study detected five strains those were possessing CTX-15 enzyme i.e. pandemic strains from received clinical sample from NICU and PICU. This distressing the situation and affecting on social as well as economical burden. Our hospital is tertiary care hospital and we are also receiving admission of patents those were critically ill and received treatment from outside most of the time. We are now taking efforts to reduce the spreading and disseminating such strains inside the hospital and among hospitalized patients. More recently, systematic attempts have been made to look at clinical outcomes of bacteria caused by ESBL-producing E. coli and Klebseilla pneumonia strains reviewed by Peterson, et al [19] . The studies described by Nichols Chanoin, et al [20] that bacteremia caused by ESBL-producing strains is associated with a higher mortality rate and early administration of carbapenem use may reduce the rate of mortality among patients with infections caused by ESBL-producing organisms [15] [16] [17] [18] [19] [20] . Tsu-Lan Wu, et al (2003) reported growing trend of ESBL producing Enterobacteriaceae in PICU in Taiwan [20] [21] [22] [22] [23] [24] [25] .
Implementation
The increase in the number of ESBL-producing isolates by Entero-Jadhav S.V., Jadhav R., Gandham N., Misra R., Singh P., Ujagare M., Angadi K. and Vyawahare C. bacteriaceae in PICUs outbreaks were reported by several authors worldwide. The dissemination of ESBL-producing Enterobacteriaceae is a consequence of the clonal expansion of a few epidemic strains and the spread of resistance plasmids among bacterial organisms which has been associated with community as well as hospital acquired. Since the resistance displayed by bacteria reflects the environment in which the organism thrives, immediate action, including reinforcement of infection control measures, should be taken to prevent further spread of the resistant bacteria. This study will highlights the need for monitoring the spread of this multidrug -resistant clonal complex throughout the nation and provides better understanding of the contribution of clonal dissemination among multidrug resistance Gram negative pathogens.
Conclusion
The emergence and spread of antimicrobial resistance is promoted by two factors: lapses in infection control and antibiotic selective pressure. ESBL producing gram negative bacteria should be best controlled by limiting the use of extended-spectrum cephalosporins in general and Ceftazidime in particular.
